0000891293-17-000106.txt : 20171003
0000891293-17-000106.hdr.sgml : 20171003
20171003161216
ACCESSION NUMBER: 0000891293-17-000106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170929
FILED AS OF DATE: 20171003
DATE AS OF CHANGE: 20171003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIRSKE DAVID
CENTRAL INDEX KEY: 0001276750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 171117960
MAIL ADDRESS:
STREET 1: C/O CTI BIOPHARMA CORP.
STREET 2: 3101 WESTERN AVE., SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2017-09-29
0
0000891293
CTI BIOPHARMA CORP
ctic
0001276750
KIRSKE DAVID
3101 WESTERN AVE., SUITE 600
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Financial Officer
Non-Qualified Stock Option (right to buy)
3.19
2017-09-29
4
A
0
315000
0
A
2027-09-29
Common Stock
315000
315000
D
The stock options will vest in six equal semi-annual installments over a three-year period beginning September 29, 2017 subject to continued employment by CTIC through the applicable vesting dates.
Bruce J. Seeley, Attorney-in-fact For: David Kirske
2017-10-03